Switch to:
Also traded in: Denmark, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 12.67
NVO's Cash-to-Debt is ranked lower than
51% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NVO: 12.67 )
Ranked among companies with meaningful Cash-to-Debt only.
NVO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 4.77 Max: 90.39
Current: 12.67
0.29
90.39
Equity-to-Asset 0.50
NVO's Equity-to-Asset is ranked lower than
76% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NVO: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
NVO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.62 Max: 0.73
Current: 0.5
0.42
0.73
Debt-to-Equity 0.04
NVO's Debt-to-Equity is ranked higher than
93% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NVO: 0.04 )
Ranked among companies with meaningful Debt-to-Equity only.
NVO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.05 Max: 0.54
Current: 0.04
0.01
0.54
Interest Coverage 31.45
NVO's Interest Coverage is ranked lower than
73% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NVO: 31.45 )
Ranked among companies with meaningful Interest Coverage only.
NVO' s Interest Coverage Range Over the Past 10 Years
Min: 9.18  Med: 279.29 Max: 884.41
Current: 31.45
9.18
884.41
Piotroski F-Score: 6
Altman Z-Score: 13.20
Beneish M-Score: -2.91
WACC vs ROIC
9.76%
153.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 44.22
NVO's Operating Margin % is ranked higher than
96% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NVO: 44.22 )
Ranked among companies with meaningful Operating Margin % only.
NVO' s Operating Margin % Range Over the Past 10 Years
Min: 21.38  Med: 35.7 Max: 45.81
Current: 44.22
21.38
45.81
Net Margin % 33.81
NVO's Net Margin % is ranked higher than
94% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NVO: 33.81 )
Ranked among companies with meaningful Net Margin % only.
NVO' s Net Margin % Range Over the Past 10 Years
Min: 20.38  Med: 26.62 Max: 33.93
Current: 33.81
20.38
33.93
ROE % 88.59
NVO's ROE % is ranked higher than
99% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NVO: 88.59 )
Ranked among companies with meaningful ROE % only.
NVO' s ROE % Range Over the Past 10 Years
Min: 27.38  Med: 50.43 Max: 82.23
Current: 88.59
27.38
82.23
ROA % 41.50
NVO's ROA % is ranked higher than
98% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NVO: 41.50 )
Ranked among companies with meaningful ROA % only.
NVO' s ROA % Range Over the Past 10 Years
Min: 18.46  Med: 30 Max: 41.29
Current: 41.5
18.46
41.29
ROC (Joel Greenblatt) % 170.01
NVO's ROC (Joel Greenblatt) % is ranked higher than
96% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NVO: 170.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 43  Med: 107.33 Max: 178.92
Current: 170.01
43
178.92
3-Year Revenue Growth Rate 12.40
NVO's 3-Year Revenue Growth Rate is ranked higher than
64% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NVO: 12.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NVO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -46.3  Med: 12.4 Max: 127.9
Current: 12.4
-46.3
127.9
3-Year EBITDA Growth Rate 15.30
NVO's 3-Year EBITDA Growth Rate is ranked higher than
67% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NVO: 15.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -44.4  Med: 14.7 Max: 130.3
Current: 15.3
-44.4
130.3
3-Year EPS without NRI Growth Rate 17.00
NVO's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NVO: 17.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 16.7 Max: 36.9
Current: 17
1.3
36.9
GuruFocus has detected 4 Warning Signs with Novo Nordisk A/S $NVO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVO's 30-Y Financials

Financials (Next Earnings Date: 2017-10-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

NVO Guru Trades in Q3 2016

Jim Simons 14,653,500 sh (+13.16%)
Murray Stahl 7,787 sh (+0.61%)
Spiros Segalas 7,212,304 sh (+16.71%)
Tom Gayner 1,075,000 sh (unchged)
Ruane Cunniff 94,165 sh (unchged)
Mario Gabelli Sold Out
Ken Fisher 10,910,669 sh (-0.48%)
Jeremy Grantham 61,700 sh (-29.57%)
» More
Q4 2016

NVO Guru Trades in Q4 2016

Murray Stahl 7,787 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Jeremy Grantham Sold Out
Spiros Segalas Sold Out
Ken Fisher 10,621,538 sh (-2.65%)
Jim Simons 13,945,900 sh (-4.83%)
Ruane Cunniff 43,687 sh (-53.61%)
» More
Q1 2017

NVO Guru Trades in Q1 2017

Jim Simons 16,409,200 sh (+17.66%)
Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,740 sh (-0.60%)
Ken Fisher 10,359,005 sh (-2.47%)
Ruane Cunniff 38,770 sh (-11.26%)
» More
Q2 2017

NVO Guru Trades in Q2 2017

Ken Fisher 11,690,997 sh (+12.86%)
Murray Stahl 7,740 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Ruane Cunniff Sold Out
Jim Simons 13,534,300 sh (-17.52%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Add 12.86%0.09%$34.28 - $44.44 $ 49.2222%11,690,997
Ruane Cunniff 2017-06-30 Sold Out 0.01%$34.28 - $44.44 $ 49.2222%0
Ken Fisher 2017-03-31 Reduce -2.47%0.02%$32.98 - $37.06 $ 49.2241%10,359,005
Ruane Cunniff 2017-03-31 Reduce -11.26%$32.98 - $37.06 $ 49.2241%38,770
Ken Fisher 2016-12-31 Reduce -2.65%0.02%$31.57 - $41.52 $ 49.2236%10,621,538
Ruane Cunniff 2016-12-31 Reduce -53.61%0.02%$31.57 - $41.52 $ 49.2236%43,687
Ken Fisher 2016-09-30 Reduce -0.48%0.01%$41.59 - $57.05 $ 49.22-1%10,910,669
Mario Gabelli 2016-09-30 Sold Out $41.59 - $57.05 $ 49.22-1%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:OCSE:NZYM B, OCSE:GEN, OCSE:ALK B, OCSE:BAVA, NAS:ASND, OCSE:ZEAL, NAS:FWP, OSTO:SANION, OSTO:NUE, OTCPK:DDRT, OCSE:NEUR, XSAT:INIT » details
Traded in other countries:NOVO B.Denmark, NOVA.Germany, NVON.Mexico, NOVOB.Switzerland, 0QIU.UK, NONOF.USA,
Headquarter Location:Denmark
Novo Nordisk A/S is a healthcare company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company's business segments include, diabetes and obesity care, and biopharmaceuticals.

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, as well as oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Top Ranked Articles about Novo Nordisk A/S

Novo Nordisk announces conclusion of U.S. federal investigation of marketing practices
Victoza® (liraglutide) is approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of three major adverse cardiovascular events
3 Companies Aiming to Significantly Reduce Diabetes Treatment Costs Diabetes accounts for nearly 10% of US health care spending
Total U.S. health care spending in 2015 was an astronomical $3.2 trillion. That is 16% of the entire national debt. As much as we blame the prices of new drugs for this gargantuan sum, one of the biggest chunks of it comes from diabetes, a disease whose treatment has not changed all that much since 1922. According to the American Diabetes Association, diabetes accounts for $322 billion in total U.S. health care spending as of 2016. Read more...
Score Big Returns With Dividend Growth Companies Backtesting identifies winning investing strategies for 2017
Among U.S. companies, high dividend yield companies like Cisco Systems Inc. (NASDAQ:CSCO), Infosys Ltd. (NYSE:INFY), Novo Nordisk A/S (NYSE:NVO), Strum Ruger & Co. Inc. (NYSE:RGR) and Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:TSM) generated high portfolio returns during the backtesting period from January 2006 to January 2017. Read more...
Novo Nordisk and Glooko advance their digital health collaboration with launch of unique integrated app for improved diabetes management
FDA Approves New Novo Nordisk Treatment for Patients with Hemophilia
Novo Nordisk Launches Xultophy® 100/3.6 (insulin degludec and liraglutide injection) in the United States
Novo Nordisk Invites the Community to Unmask Everyday Heroes in Recognition of World Hemophilia Day
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novo Nordisk A/S of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017 – NVO

NEW YORK, March 08, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired American Depositary Receipts of Novo Nordisk A/S (:NVO) between February 5, 2015 and October 27, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to: http://www.zlk.com/pslra/novo-nordisk-as or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that during the Class Period, Novo Nordisk issued materially false and misleading earnings and forecasts; said reports were inflated by collusive price fixing concerning the Company’s insulin drugs. The complaint further alleges that the Company misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers. If you suffered a loss in Novo Nordisk you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...
NVO Lead Plaintiff Deadline Reminder: Hagens Berman Reminds Novo Nordisk Investors of March 13, 2017 Lead Plaintiff Deadline

SAN FRANCISCO, March 06, 2017 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Novo Nordisk A/S (:NVO) of the March 13, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired securities of NVO between February 5, 2015 and October 27, 2016 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit: https://www.hbsslaw.com/cases/NVO or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected]. On October 28, 2016, after repeatedly assuring investors of sales and profit growth, NVO announced its second consecutive quarter of disappointing earnings and slashed long-term profit-growth forecasts by 50%.  The Company also revealed it was under investigation by the U.S. Attorney’s Office for potentially improper arrangements with pharmacy benefits managers who purchase NVO’s insulin products.  This news drove the price of the Company’s ADRs down approximately 13%. “We’re focused on NVO’s insulin- and other- pricing matters and Defendants’ growth-related statements,” said Hagens Berman partner Reed Kathrein. Whistleblowers: Persons with non-public information regarding NVO should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email [email protected]. About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities.  The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000

Read more...

Ratios

vs
industry
vs
history
PE Ratio 19.86
NVO's PE Ratio is ranked higher than
72% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. NVO: 19.86 )
Ranked among companies with meaningful PE Ratio only.
NVO' s PE Ratio Range Over the Past 10 Years
Min: 12.13  Med: 23.55 Max: 34.41
Current: 19.86
12.13
34.41
Forward PE Ratio 18.55
NVO's Forward PE Ratio is ranked higher than
63% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. NVO: 18.55 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 19.86
NVO's PE Ratio without NRI is ranked higher than
73% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. NVO: 19.86 )
Ranked among companies with meaningful PE Ratio without NRI only.
NVO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.13  Med: 23.51 Max: 34.41
Current: 19.86
12.13
34.41
Price-to-Owner-Earnings 23.08
NVO's Price-to-Owner-Earnings is ranked higher than
68% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. NVO: 23.08 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NVO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.62  Med: 26.72 Max: 60.24
Current: 23.08
15.62
60.24
PB Ratio 15.68
NVO's PB Ratio is ranked lower than
91% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NVO: 15.68 )
Ranked among companies with meaningful PB Ratio only.
NVO' s PB Ratio Range Over the Past 10 Years
Min: 3.68  Med: 10.96 Max: 31.9
Current: 15.68
3.68
31.9
PS Ratio 6.72
NVO's PS Ratio is ranked higher than
66% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. NVO: 6.72 )
Ranked among companies with meaningful PS Ratio only.
NVO' s PS Ratio Range Over the Past 10 Years
Min: 2.81  Med: 5.97 Max: 10.99
Current: 6.72
2.81
10.99
Price-to-Free-Cash-Flow 19.30
NVO's Price-to-Free-Cash-Flow is ranked higher than
69% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. NVO: 19.30 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NVO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.75  Med: 24.24 Max: 46.97
Current: 19.3
12.75
46.97
Price-to-Operating-Cash-Flow 15.81
NVO's Price-to-Operating-Cash-Flow is ranked higher than
74% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. NVO: 15.81 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NVO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.65  Med: 19.83 Max: 32.48
Current: 15.81
10.65
32.48
EV-to-EBIT 15.05
NVO's EV-to-EBIT is ranked higher than
67% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. NVO: 15.05 )
Ranked among companies with meaningful EV-to-EBIT only.
NVO' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.1  Med: 16.7 Max: 25.7
Current: 15.05
10.1
25.7
EV-to-EBITDA 14.10
NVO's EV-to-EBITDA is ranked higher than
63% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. NVO: 14.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.6  Med: 16 Max: 23.6
Current: 14.1
9.6
23.6
EV-to-Revenue 6.66
NVO's EV-to-Revenue is ranked higher than
67% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. NVO: 6.66 )
Ranked among companies with meaningful EV-to-Revenue only.
NVO' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.7  Med: 5.7 Max: 10.9
Current: 6.66
2.7
10.9
PEG Ratio 1.15
NVO's PEG Ratio is ranked higher than
66% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. NVO: 1.15 )
Ranked among companies with meaningful PEG Ratio only.
NVO' s PEG Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.14 Max: 5.14
Current: 1.15
0.7
5.14
Shiller PE Ratio 34.87
NVO's Shiller PE Ratio is ranked higher than
70% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. NVO: 34.87 )
Ranked among companies with meaningful Shiller PE Ratio only.
NVO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 24.87  Med: 42.54 Max: 68.04
Current: 34.87
24.87
68.04
Current Ratio 1.35
NVO's Current Ratio is ranked lower than
87% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. NVO: 1.35 )
Ranked among companies with meaningful Current Ratio only.
NVO' s Current Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.96 Max: 3.09
Current: 1.35
1.04
3.09
Quick Ratio 1.00
NVO's Quick Ratio is ranked lower than
87% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. NVO: 1.00 )
Ranked among companies with meaningful Quick Ratio only.
NVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.32 Max: 2.6
Current: 1
0.74
2.6
Days Inventory 300.50
NVO's Days Inventory is ranked lower than
85% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. NVO: 300.50 )
Ranked among companies with meaningful Days Inventory only.
NVO' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 282.52 Max: 343.56
Current: 300.5
246.45
343.56
Days Sales Outstanding 55.50
NVO's Days Sales Outstanding is ranked higher than
59% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. NVO: 55.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.9 Max: 66.07
Current: 55.5
45.09
66.07
Days Payable 88.47
NVO's Days Payable is ranked higher than
65% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. NVO: 88.47 )
Ranked among companies with meaningful Days Payable only.
NVO' s Days Payable Range Over the Past 10 Years
Min: 72.54  Med: 100.02 Max: 127.69
Current: 88.47
72.54
127.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.31
NVO's Dividend Yield % is ranked higher than
86% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. NVO: 2.31 )
Ranked among companies with meaningful Dividend Yield % only.
NVO' s Dividend Yield % Range Over the Past 10 Years
Min: 0.93  Med: 1.6 Max: 4.17
Current: 2.31
0.93
4.17
Dividend Payout Ratio 0.50
NVO's Dividend Payout Ratio is ranked lower than
69% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. NVO: 0.50 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NVO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.35 Max: 0.63
Current: 0.5
0.26
0.63
3-Year Dividend Growth Rate 37.70
NVO's 3-Year Dividend Growth Rate is ranked higher than
86% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. NVO: 37.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NVO' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -2.1  Med: 18.6 Max: 37.7
Current: 37.7
-2.1
37.7
Forward Dividend Yield % 1.92
NVO's Forward Dividend Yield % is ranked higher than
90% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.26 vs. NVO: 1.92 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 9.26
NVO's 5-Year Yield-on-Cost % is ranked higher than
94% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. NVO: 9.26 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NVO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.71  Med: 6.35 Max: 16.65
Current: 9.26
3.71
16.65
3-Year Average Share Buyback Ratio 1.80
NVO's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NVO: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: 0.7 Max: 8
Current: 1.8
-13.6
8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 79.23
NVO's Price-to-Net-Current-Asset-Value is ranked lower than
100% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. NVO: 79.23 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NVO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 11.79  Med: 25.05 Max: 696.47
Current: 79.23
11.79
696.47
Price-to-Tangible-Book 16.59
NVO's Price-to-Tangible-Book is ranked lower than
88% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. NVO: 16.59 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.14  Med: 7.83 Max: 31.52
Current: 16.59
3.14
31.52
Price-to-Intrinsic-Value-Projected-FCF 1.67
NVO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
79% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. NVO: 1.67 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NVO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.36  Med: 2.32 Max: 7.38
Current: 1.67
1.36
7.38
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.70
NVO's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
85% of the 26 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NVO: 0.70 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
NVO' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.48  Med: 0.9 Max: 1.14
Current: 0.7
0.48
1.14
Price-to-Median-PS-Value 1.13
NVO's Price-to-Median-PS-Value is ranked lower than
57% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. NVO: 1.13 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.82 Max: 1.75
Current: 1.13
0.13
1.75
Price-to-Peter-Lynch-Fair-Value 1.09
NVO's Price-to-Peter-Lynch-Fair-Value is ranked higher than
80% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. NVO: 1.09 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
NVO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.19  Med: 1.01 Max: 3.78
Current: 1.09
0.19
3.78
Price-to-Graham-Number 3.83
NVO's Price-to-Graham-Number is ranked lower than
65% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. NVO: 3.83 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NVO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.58  Med: 2.82 Max: 6.75
Current: 3.83
1.58
6.75
Earnings Yield (Greenblatt) % 6.64
NVO's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. NVO: 6.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.9  Med: 6 Max: 9.9
Current: 6.64
3.9
9.9
Forward Rate of Return (Yacktman) % 21.97
NVO's Forward Rate of Return (Yacktman) % is ranked higher than
63% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. NVO: 21.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NVO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.5  Med: 22.9 Max: 33.5
Current: 21.97
7.5
33.5

More Statistics

Revenue (TTM) (Mil) $16,757.43
EPS (TTM) $ 2.26
Beta0.51
Short Percentage of Float0.00%
52-Week Range $30.89 - 49.26
Shares Outstanding (Mil)2,550.00 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 18,326 19,355 20,838
EPS ($) 2.49 2.67 2.83
EPS without NRI ($) 2.49 2.67 2.83
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.49%
Dividends per Share ($) 1.43 1.53 1.89

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}